| GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma (NCT03731390) | Chinese Academy of Medical Sciences | 2018-11-01 |
| Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer (NCT03654716) | Dana-Farber Cancer Institute | 2018-11-01 |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (NCT03602157) | UNC Lineberger Comprehensive Cancer Center | 2018-10-29 |
| A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas (NCT03809767) | CStone Pharmaceuticals | 2018-10-29 |
| Image-guided Lymphadanectomy in AMIGO (NCT03283423) | Brigham and Women's Hospital | 2018-10-25 |
| RPTR-147 in Patients With Selected Solid Tumors and Lymphomas (NCT03815682) | Repertoire Immune Medicines | 2018-10-24 |
| Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma (NCT03682796) | Triphase Research and Development III Corp. | 2018-10-15 |
| BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma (NCT03264131) | UNC Lineberger Comprehensive Cancer Center | 2018-10-11 |
| Effect on Patient Quality of Life of Taking Into Account the Spiritual Dimension in Nurse's Care for Haematologic Cancers. (NCT03698656) | University Hospital, Toulouse | 2018-10-10 |
| Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. (NCT03544723) | MultiVir, Inc. | 2018-10-01 |
| A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System (NCT03648372) | Takeda | 2018-10-01 |
| Resiliency in Older Adults Undergoing Bone Marrow Transplant (NCT04188678) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-09-28 |
| Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant (NCT03588936) | Medical College of Wisconsin | 2018-09-14 |
| Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas (NCT03187210) | Insel Gruppe AG, University Hospital Bern | 2018-09-01 |
| SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart (NCT03574012) | Fred Hutchinson Cancer Center | 2018-08-31 |
| A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) (NCT03314922) | Incyte Corporation | 2018-08-02 |
| PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy (NCT03647072) | Sherief Abd-Elsalam | 2018-08-01 |
| Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (NCT03524235) | Noah Merin | 2018-07-18 |
| Clinical Application of Liquid Biopsy for Precise Diagnosis and Prognosis in Lymphoma (NCT04062877) | Ge Zheng | 2018-07-01 |
| Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma (NCT03283111) | Peking University | 2018-07-01 |
| ARQ761 + PARP Inhibitor in Refractory Solid Tumors (NCT03575078) | University of Texas Southwestern Medical Center | 2018-06-25 |
| Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS) (NCT03476070) | National University of Singapore | 2018-06-18 |
| Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas (NCT03489343) | Symphogen A/S | 2018-05-24 |
| A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (NCT03530683) | Pfizer | 2018-05-14 |
| Geriatric Communication Skills Training Program for Oncology Clinicians (NCT03530969) | Memorial Sloan Kettering Cancer Center | 2018-05-07 |
| Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant (NCT03057054) | Children's Oncology Group | 2018-04-30 |
| Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas (NCT03258567) | National Cancer Institute (NCI) | 2018-04-26 |
| Trial Comparing Active Intervention At Diagnosis With Usual Care to Improve Psycho-social Care in AYAO (NCT03515174) | National Cancer Centre, Singapore | 2018-04-16 |
| CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma (NCT03488160) | Sinobioway Cell Therapy Co., Ltd. | 2018-04-10 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression (NCT03480360) | Dartmouth-Hitchcock Medical Center | 2018-03-28 |
| Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma (NCT03465891) | Memorial Sloan Kettering Cancer Center | 2018-03-09 |
| Phase I/II Study of Avelumab in Pediatric Cancer Participants (NCT03451825) | EMD Serono Research & Development Institute, Inc. | 2018-03-07 |
| Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma (NCT03361358) | Agios Pharmaceuticals, Inc. | 2018-03-01 |
| A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL (NCT03494296) | First Affiliated Hospital of Harbin Medical University | 2018-03-01 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206) | Shenzhen BinDeBio Ltd. | 2018-03-01 |
| Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy. (NCT03137537) | Dana-Farber Cancer Institute | 2018-02-27 |
| Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology (NCT06335277) | European Institute of Oncology | 2018-02-22 |
| The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of Lymphoma (NCT03973164) | Guangxi Medical University | 2018-02-02 |
| Pediatric PET/MR Image Registry (NCT03458520) | Stanford University | 2018-02-01 |
| Exercise as an Immune Adjuvant for Allogeneic Cell Therapies (NCT06643221) | University of Arizona | 2018-01-24 |
| UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma (NCT03322384) | University of California, Davis | 2018-01-17 |
| Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma (NCT03468153) | Ruijin Hospital | 2018-01-01 |
| A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) (NCT03144674) | Incyte Corporation | 2017-12-18 |
| A Multi-center, Prospective, Single-blind, Controlled Trial Comparing Diagnostic Value of Different EUS-FNA Techniques (NCT03674710) | Shanghai Zhongshan Hospital | 2017-12-18 |
| Pembrolizumab in Neoplasms or Lymphomas (NCT03316573) | Dana-Farber Cancer Institute | 2017-12-07 |
| Evaluation Study of Fear of Cancer Recurrence: Detection, Measure and Risk Factors in Lymphoma Survivorship (NCT03260855) | University Hospital, Toulouse | 2017-11-28 |
| A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor (NCT03235544) | Incyte Corporation | 2017-11-20 |
| Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas (NCT03311412) | Symphogen A/S | 2017-11-20 |
| A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients (NCT03352765) | Memorial Sloan Kettering Cancer Center | 2017-11-20 |
| Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation (NCT03373526) | Daniel Godoy Martinez | 2017-11-11 |
| Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer (NCT03408561) | University of Southern California | 2017-11-08 |
| A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia (NCT03330691) | Seattle Children's Hospital | 2017-11-03 |
| WB-EMS and Nutrition in Patients With Hematological Malignancies (NCT03556748) | University of Erlangen-Nürnberg Medical School | 2017-11-01 |
| Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (NCT03374007) | Genor Biopharma Co., Ltd. | 2017-10-19 |
| Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma (NCT03189836) | Cogent Biosciences, Inc. | 2017-10-04 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278) | Rutgers, The State University of New Jersey | 2017-10-03 |
| Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL (NCT02656147) | Beijing Doing Biomedical Co., Ltd. | 2017-10-01 |
| FDG PET/CT and Directed Metabolic Core Needle Biopsy in the Management of Lymphoma (NCT05186610) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2017-10-01 |
| The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma (NCT03295240) | Memorial Sloan Kettering Cancer Center | 2017-09-20 |
| FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma (NCT01410630) | Jonsson Comprehensive Cancer Center | 2017-09-07 |
| CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies (NCT03312205) | Hebei Senlang Biotechnology Inc., Ltd. | 2017-08-29 |
| Sample Collection and Tracking for the Developmental Therapeutics Clinic (NCT03269578) | National Cancer Institute (NCI) | 2017-08-28 |
| A Randomized Study Evaluating the Incidence of Post Lumbar Puncture Headache With Atraumatic Needles in Hematology (NCT03126045) | Centre Hospitalier Universitaire de Saint Etienne | 2017-08-22 |
| Retrospective Analysis of Lymphomas and Cancers Synchronous Occurrence in Picardy From 2007 to 2012 (NCT03135743) | Centre Hospitalier Universitaire, Amiens | 2017-08-20 |
| Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies (NCT03262298) | Affiliated Hospital to Academy of Military Medical Sciences | 2017-08-20 |
| Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing (NCT03226704) | National Cancer Institute (NCI) | 2017-08-14 |
| Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma (NCT03212261) | Massachusetts General Hospital | 2017-08-03 |
| Liquid Biopsy Evaluation and Repository Development at Princess Margaret (NCT03702309) | University Health Network, Toronto | 2017-08-03 |
| Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group (NCT03141398) | Hamad Medical Corporation | 2017-08-01 |
| Lonquek for Autologous Stem Cell Mobilization (NCT02488382) | Sheba Medical Center | 2017-07-01 |
| Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma (NCT03054532) | Singapore General Hospital | 2017-07-01 |
| A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies (NCT03191773) | Second Affiliated Hospital of Guangzhou Medical University | 2017-06-30 |
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas (NCT03205176) | AstraZeneca | 2017-06-30 |
| The CAROLE (CArdiac Related Oncologic Late Effects) Study (NCT03235427) | Northwell Health | 2017-06-27 |
| Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy (NCT03144583) | Sara V. Latorre | 2017-06-15 |
| Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma (NCT03151876) | Sichuan University | 2017-06-12 |
| Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas (NCT03179930) | Memorial Sloan Kettering Cancer Center | 2017-06-07 |
| Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma (NCT02961816) | M.D. Anderson Cancer Center | 2017-06-01 |
| Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL) (NCT03098589) | Celgene | 2017-05-30 |
| China Lymphoma Patient Registry Study (NCT03313271) | Jun Zhu | 2017-05-17 |
| Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas (NCT03119467) | Rhizen Pharmaceuticals SA | 2017-05-11 |
| Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma (NCT02724904) | Massachusetts General Hospital | 2017-05-01 |
| Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer (NCT03141437) | M.D. Anderson Cancer Center | 2017-04-23 |
| CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma (NCT03118180) | Zhejiang University | 2017-04-05 |
| Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma (NCT03086954) | Sinobioway Cell Therapy Co., Ltd. | 2017-04-01 |
| A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) (NCT02998476) | Incyte Corporation | 2017-03-02 |
| Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides (NCT03454945) | Cairo University | 2017-03-01 |
| Phase II Study of TAK228 in Relapsed Lymphoma (NCT02727777) | M.D. Anderson Cancer Center | 2017-03-01 |
| Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas (NCT03030417) | National Cancer Institute (NCI) | 2017-02-27 |
| Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer Survivors (NCT03052777) | University of Alberta | 2017-02-21 |
| Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma (NCT02898259) | Brian Hill | 2017-02-20 |
| Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study (NCT03245788) | Stanford University | 2017-02-15 |
| Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) (NCT03039114) | Incyte Corporation | 2017-02-15 |
| A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type (NCT02927925) | Janssen Research & Development, LLC | 2017-02-14 |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (NCT03058289) | Intensity Therapeutics, Inc. | 2017-02-09 |
| A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies (NCT02937675) | Effector Therapeutics | 2017-02-08 |
| Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) (NCT03010176) | Merck Sharp & Dohme LLC | 2017-02-03 |
| The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function (NCT03062878) | Carl Ade, M.S., Ph.D. | 2017-02-01 |
| PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas (NCT03013491) | CytomX Therapeutics | 2017-01-19 |